Salma Health

Salma Health operates at the intersection of mental healthcare delivery, neuropsychiatry, diagnostics and clinical research. Its positioning differs from narrower virtual-therapy providers because the model combines licensed clinical care with interventional psychiatry, measurement-based treatment, advanced diagnostics and research activities. It also differs from single-modality clinics by offering TMS, SAINT, Spravato and ketamine-based therapies alongside behavioral and psychiatric care. The proprietary AI-driven platform is intended to match patients with treatments based on biology and individual needs, giving the company a technology layer beyond conventional provider operations. Its integrated model may support more continuity than fragmented specialty care, but it also creates operational and reimbursement complexity. The $80 million Series A and Center of Excellence launch indicate that investors are backing a scaled, research-oriented brain-health platform rather than a standalone clinic concept.

Salma Health’s trajectory shows a transition from an early-stage brain-health provider toward a more integrated clinical and technology platform. The clearest inflection point came on Feb 26, 2026, when the company announced an $80 million Series A led by Mubadala Capital and ARCH Venture Partners alongside the launch of its Brain Health Center of Excellence. That combination suggests capital is being directed toward infrastructure, clinical expansion, research and product development rather than only incremental clinic growth. The company’s model spans in-person clinics and virtual care, while its AI-driven treatment-matching platform is designed to connect diagnostics with treatment selection. Hiring activity focused on clinicians and staff indicates that capacity expansion is an immediate execution priority. The company also maintains a clinical research emphasis across psychiatric, neurological and brain-injury conditions, which could create longer-term differentiation but may extend commercialization timelines.